# A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Source: https://onco.cc/trials/nct02966756/  
OnCo record `nct02966756` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Venetoclax in chronic lymphocytic leukaemia, run by AbbVie, active and no longer recruiting.

## Summary

A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma is a phase 2 interventional study registered as NCT02966756 by AbbVie, with 66 participants enrolled, started 2017-10-12 and due to reach its primary completion in 2030-12. Interventions recorded: Venetoclax.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02966756
- Phase: 2
- Setting: A Phase 2 Open-Label Study of the Efficacy of Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Sponsor: AbbVie
- Enrolled: 66

## Sources

- ClinicalTrials.gov NCT02966756: https://clinicaltrials.gov/study/NCT02966756

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/)
- drugs: [Venetoclax](https://onco.cc/drugs/venetoclax/)
- companies: [AbbVie (incl. ImmunoGen, Capstan)](https://onco.cc/companies/abbvie/)

---
JSON: https://onco.cc/api/v1/entities/nct02966756.json